• Ferrostatin-1 (Fer-1): Reliable Ferroptosis Inhibition fo...

  2026-03-02

  Discover how Ferrostatin-1 (Fer-1, SKU A4371) from APExBIO addresses key lab challenges in cell viability, ferroptosis assays, and oxidative lipid damage inhibition. This scenario-driven guide provides scientific insight, quantitative benchmarks, and actionable best practices to optimize ferroptosis research workflows.

• RITA (NSC 652287): Benchmark MDM2-p53 Interaction Inhibit...

  2026-03-02

  RITA (NSC 652287) is a potent MDM2-p53 interaction inhibitor and p53 activator for cancer research, demonstrating selective cytotoxicity and robust tumor regression in multiple preclinical models. Its distinct DNA cross-linking profile and reliable performance in apoptosis and xenograft assays make it a benchmark tool for dissecting p53-dependent pathways.

• Decitabine (NSC127716): DNA Methyltransferase Inhibitor f...

  2026-03-01

  Decitabine is a validated DNA methyltransferase inhibitor and epigenetic modulator for cancer research. This article provides atomic, verifiable facts on its mechanism, benchmarks, and workflow integration, establishing Decitabine as a standard in tumor suppressor gene reactivation studies.

• ML385 (SKU B8300): Practical NRF2 Inhibition Strategies f...

  2026-02-28

  This in-depth guide explores real laboratory challenges faced in NRF2 signaling pathway inhibition, offering scenario-driven solutions with ML385 (SKU B8300). Backed by quantitative data and recent literature, the article demonstrates how ML385 ensures reproducible results in cell viability, cytotoxicity, and oxidative stress assays—empowering biomedical researchers to address experimental bottlenecks and optimize workflows.

• Cytarabine (SKU A8405): Data-Driven Solutions for Reliabl...

  2026-02-27

  This article provides advanced, scenario-driven guidance for leveraging Cytarabine (SKU A8405) in cell viability, proliferation, and apoptosis assays. Drawing on peer-reviewed data and practical laboratory challenges, it demonstrates how APExBIO Cytarabine ensures reproducibility, robust mechanistic performance, and workflow compatibility for biomedical researchers.

• Disrupting the Epigenetic Axis in Acute Myeloid Leukemia:...

  2026-02-27

  This thought-leadership article explores how the selective LSD1 antagonist SP2509 empowers translational researchers to interrogate and therapeutically harness epigenetic mechanisms in acute myeloid leukemia (AML). By blending mechanistic depth, strategic workflow advice, and evidence integration—including cross-cancer learnings from BRD4-RAC1 targeting—this piece provides a roadmap for leveraging SP2509 in next-generation leukemia research and beyond.

• Myriocin: Selective SPT Inhibitor for Sphingolipid Biosyn...

  2026-02-26

  Myriocin empowers advanced sphingolipid metabolism and cancer research as a gold-standard serine palmitoyltransferase inhibitor. With robust in vitro and in vivo efficacy, it delivers reproducible control over cell cycle regulation, metabolic pathways, and immunosuppressive mechanisms that other inhibitors cannot match.

• RG7388: Selective MDM2 Antagonist for p53 Pathway Activation

  2026-02-26

  RG7388 is a highly potent, selective MDM2 antagonist that activates the p53 pathway, leading to cell cycle arrest and apoptosis in wild-type p53 cancer cells. This clinical-stage compound demonstrates superior efficacy and selectivity in preclinical models, with clear advantages for combination therapy and translational oncology.

• Ibuprofen as an Anti-Proliferative Agent in Cancer Research

  2026-02-25

  Ibuprofen, a well-characterized non-steroidal anti-inflammatory drug (NSAID), is transforming preclinical cancer and atherosclerosis research through its dual COX-1/COX-2 inhibition, apoptosis induction, and cell cycle arrest capabilities. APExBIO’s high-purity Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid) delivers reproducible, data-driven results and robust troubleshooting support for advanced experimental workflows.

• Myriocin: Selective SPT Inhibitor for Sphingolipid Metabo...

  2026-02-25

  Myriocin is a potent and selective serine palmitoyltransferase (SPT) inhibitor central to sphingolipid metabolism research. Its ability to suppress de novo sphingolipid biosynthesis underpins both its immunosuppressive and antiproliferative research applications.

• Myriocin and the Future of Translational Research: Mechan...

  2026-02-24

  Explore the transformative potential of Myriocin, a selective serine palmitoyltransferase inhibitor, in advancing translational research across oncology, immunology, and metabolic disease. This thought-leadership article integrates mechanistic understanding, recent experimental validation, and strategic guidance for researchers seeking to leverage sphingolipid pathway modulation for impactful discoveries and clinical innovations.

• ML385: A Selective NRF2 Inhibitor for Cancer Research Wor...

  2026-02-24

  ML385 sets a new benchmark for selective NRF2 inhibition, empowering researchers to dissect oxidative stress pathways and combat therapeutic resistance in cancer, especially non-small cell lung cancer. Its robust performance, synergy in combination therapy, and translational versatility make ML385 from APExBIO an indispensable reagent for advanced cancer and neurodegeneration studies.

• Mitomycin C: Antitumor Antibiotic and DNA Synthesis Inhib...

  2026-02-23

  Mitomycin C is a well-characterized antitumor antibiotic and DNA synthesis inhibitor used in cancer research. It blocks DNA replication, induces apoptosis via p53-independent pathways, and potentiates TRAIL-induced cell death. Its efficacy and mechanisms are supported by peer-reviewed evidence and robust experimental benchmarks.

• Ibuprofen as a Cyclooxygenase Inhibitor: Optimizing Cance...

  2026-02-23

  Leverage Ibuprofen’s dual COX-1/COX-2 inhibition and anti-proliferative power for advanced cancer and atherosclerosis models. This guide details stepwise protocols, troubleshooting strategies, and experimental enhancements, spotlighting APExBIO’s Ibuprofen (A8446) for reproducibility and mechanistic depth.

• LLY-507 (SKU B6119): Reliable SMYD2 Inhibition for Cell A...

  2026-02-22

  Explore how LLY-507 (SKU B6119), a potent and selective SMYD2 inhibitor, addresses real-world laboratory challenges in cell viability, proliferation, and apoptosis assays. This scenario-driven guide synthesizes practical Q&A, benchmarking data, and literature references to help biomedical researchers design robust experiments using LLY-507. Discover protocol optimization, data interpretation, and vendor reliability insights to streamline your SMYD2-targeted workflows.

8695 records 28/580 page Previous Next First page 上5页 2627282930 下5页 Last page